Welcome to our dedicated page for POMDOCTOR SEC filings (Ticker: POM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on POMDOCTOR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into POMDOCTOR's regulatory disclosures and financial reporting.
POMDOCTOR Ltd filed an initial insider ownership report for Luo Guoji. The filing identifies Luo as both a director and an officer of the company, serving as Vice President. It does not list any transactions in POMDOCTOR Ltd securities in connection with this filing.
POMDOCTOR Ltd director and CEO Shi Zhenyang has filed an initial Form 3 disclosing indirect ownership of the company’s dual-class shares. The filing reports indirect holdings of Class A ordinary shares through entities including HEALTHYSEVEN LIMITED and several Guangzhou management consulting partnerships, and Class B ordinary shares through HEALTHYSEVEN LIMITED and HEALTHYTEN LIMITED.
The company’s capital structure includes Class A and Class B ordinary shares. Each Class B share carries twenty votes, while each Class A share carries one vote, and each Class B share is convertible into one Class A share at the holder’s option.
POMDOCTOR LIMITED is launching a strategic initiative to deepen integration between its online chronic-disease platform and China’s national and local medical insurance systems across major cities. This aims to broaden market reach and make reimbursed online care more convenient for patients, internet hospitals, and pharmacies.
The company already supports online insurance settlements for chronic and special disease outpatients in Guangzhou and plans expansion to other Greater Bay Area cities, including Foshan in the first quarter of 2026, as well as Beijing, Shanghai, Tianjin, Chengdu, Xi’an, Nanjing, Hangzhou, and Fuzhou. Patients can complete consultations, receive digital prescriptions, obtain near-real-time insurance reimbursement, and have medications delivered to their homes, reflecting China’s shift toward standardized, large-scale internet healthcare.
POMDOCTOR LIMITED reported that Nasdaq has notified the company its American depositary shares have failed to meet the minimum bid price requirement of US$1.00 for 33 consecutive business days. This triggers a compliance period but does not immediately affect listing or trading of the ADSs.
Under Nasdaq rules, Pomdoctor has 180 calendar days, until July 28, 2026, to regain compliance. If the ADS closing bid price is at least US$1.00 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter. The company states that the notice has no effect on its business operations and that it will take reasonable measures to regain compliance.
POMDOCTOR LIMITED filed a report describing progress in its strategic partnerships with leading domestic pharmaceutical companies to grow its internet hospital business in China. The Company plans to make these collaborations a core part of its long-term strategy to expand online hospital operations and improve profitability.
The filing highlights rapid growth in China’s online pharmaceutical market, with online drug sales rising from approximately RMB 19 billion in 2020 to about RMB 60.8 billion in 2023 and RMB 71.8 billion (approximately US$10.3 billion) in 2024, a compound annual growth rate of 39.4%. Pomdoctor, through its subsidiaries, has entered into sales and purchase agreements with several listed and innovative drug makers, enabling access to innovative and patented products on its platforms and securing purchase discounts, rebates, and incentives tied to sales targets.
The Company describes this model as a way for pharmaceutical firms to gain better channel control and more efficient marketing, while Pomdoctor benefits from direct sourcing, quality assurance, and pricing advantages. It views this flattened, digital, patient-centric supply chain collaboration as aligned with China’s healthcare reforms and as a key direction for the evolution of pharmaceutical distribution.